BACKGROUND:Bardoxolone methyl has been shown to increase eGFR in several clinical trials, including a phase 3 trial in patients with type 2 diabetes and stage 4 CKD (BEACON), which was terminated early due to an increase in heart failure events in bardoxolone methyl-treated patients. A separate, "thorough QT" study was conducted in parallel with BEACON to evaluate the cardiovascular safety of bardoxolone methyl in healthy subjects. METHODS:Subjects in the "thorough QT" study were randomized to receive bardoxolone methyl 20 mg (therapeutic dose) or 80 mg (supratherapeutic dose), placebo, or moxifloxacin (400 mg; an active comparator). ECG results and supine blood pressure measurements were analyzed. The effects of bardoxolone methyl on QT interval changes from baseline were quantified compared to the effect of placebo by calculating mean, time-matched, placebo-corrected, baseline-adjusted QTcF values (ΔΔQTcF) after 6 days of daily administration of bardoxolone methyl. RESULTS: The study was halted early due to emerging safety information from the BEACON trial; however, 142/179 patients received all doses of the study drug and completed the study. For both bardoxolone methyl-treated groups (20 and 80 mg), the upper limits of the 2-sided 90% confidence interval for ΔΔQTcF were less than the significance limit (10 ms) at all time points. Changes in blood pressure were similar in all treatment groups, and no serious adverse events were reported. CONCLUSIONS: In healthy subjects, treatment with 20 or 80 mg bardoxolone methyl did not affect the QTcF interval. The Author(s). Published by S. Karger AG, Basel.
RCT Entities:
BACKGROUND:Bardoxolone methyl has been shown to increase eGFR in several clinical trials, including a phase 3 trial in patients with type 2 diabetes and stage 4 CKD (BEACON), which was terminated early due to an increase in heart failure events in bardoxolone methyl-treated patients. A separate, "thorough QT" study was conducted in parallel with BEACON to evaluate the cardiovascular safety of bardoxolone methyl in healthy subjects. METHODS: Subjects in the "thorough QT" study were randomized to receive bardoxolone methyl 20 mg (therapeutic dose) or 80 mg (supratherapeutic dose), placebo, or moxifloxacin (400 mg; an active comparator). ECG results and supine blood pressure measurements were analyzed. The effects of bardoxolone methyl on QT interval changes from baseline were quantified compared to the effect of placebo by calculating mean, time-matched, placebo-corrected, baseline-adjusted QTcF values (ΔΔQTcF) after 6 days of daily administration of bardoxolone methyl. RESULTS: The study was halted early due to emerging safety information from the BEACON trial; however, 142/179 patients received all doses of the study drug and completed the study. For both bardoxolone methyl-treated groups (20 and 80 mg), the upper limits of the 2-sided 90% confidence interval for ΔΔQTcF were less than the significance limit (10 ms) at all time points. Changes in blood pressure were similar in all treatment groups, and no serious adverse events were reported. CONCLUSIONS: In healthy subjects, treatment with 20 or 80 mg bardoxolone methyl did not affect the QTcF interval. The Author(s). Published by S. Karger AG, Basel.
Authors: Melanie P Chin; George L Bakris; Geoffrey A Block; Glenn M Chertow; Angie Goldsberry; Lesley A Inker; Hiddo J L Heerspink; Megan O'Grady; Pablo E Pergola; Christoph Wanner; David G Warnock; Colin J Meyer Journal: Am J Nephrol Date: 2018-01-18 Impact factor: 3.754
Authors: Albena T Dinkova-Kostova; Karen T Liby; Katherine K Stephenson; W David Holtzclaw; Xiangqun Gao; Nanjoo Suh; Charlotte Williams; Renee Risingsong; Tadashi Honda; Gordon W Gribble; Michael B Sporn; Paul Talalay Journal: Proc Natl Acad Sci U S A Date: 2005-03-14 Impact factor: 11.205
Authors: D S Straus; G Pascual; M Li; J S Welch; M Ricote; C H Hsiang; L L Sengchanthalangsy; G Ghosh; C K Glass Journal: Proc Natl Acad Sci U S A Date: 2000-04-25 Impact factor: 11.205
Authors: Pablo E Pergola; Melissa Krauth; J Warren Huff; Deborah A Ferguson; Stacey Ruiz; Colin J Meyer; David G Warnock Journal: Am J Nephrol Date: 2011-04-21 Impact factor: 3.754
Authors: Melinda S Yates; Masafumi Tauchi; Fumiki Katsuoka; Kathleen C Flanders; Karen T Liby; Tadashi Honda; Gordon W Gribble; Delinda A Johnson; Jeffrey A Johnson; Neal C Burton; Tomás R Guilarte; Masayuki Yamamoto; Michael B Sporn; Thomas W Kensler Journal: Mol Cancer Ther Date: 2007-01 Impact factor: 6.261
Authors: Anna-Liisa Levonen; Aimee Landar; Anup Ramachandran; Erin K Ceaser; Dale A Dickinson; Giuseppe Zanoni; Jason D Morrow; Victor M Darley-Usmar Journal: Biochem J Date: 2004-03-01 Impact factor: 3.857
Authors: Yanfeng Ding; Rhesa D Stidham; Ron Bumeister; Isaac Trevino; Ali Winters; Marc Sprouse; Min Ding; Deborah A Ferguson; Colin J Meyer; W Christian Wigley; Rong Ma Journal: Kidney Int Date: 2012-12-12 Impact factor: 10.612
Authors: Michael B Sporn; Karen T Liby; Mark M Yore; Liangfeng Fu; Justin M Lopchuk; Gordon W Gribble Journal: J Nat Prod Date: 2011-02-10 Impact factor: 4.050